FULCRUM THERAPEUTICS, INC. Depreciation
FULCRUM THERAPEUTICS, INC. (FULC) reported Depreciation of $200.00 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. depreciation for the quarter ending 2026-06-30 was $200.00K, a 33.33% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. depreciation for the quarter ending 2026-03-31 was $338.00K, a 4.25% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $347.00K, a 5.96% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $300.00K, a 25.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. depreciation for fiscal 2023 was $2.17M, a 10.02% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. depreciation for fiscal 2022 was $2.41M, a 4.02% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. depreciation for fiscal 2021 was $2.52M, a 5.72% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. depreciation for fiscal 2020 was $2.38M, a 15.88% increase from fiscal 2019.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K S-4 · filed 2026-09-02 | $554.00K S-4 · filed 2026-09-02 | $885.00K derived: sum of 3 quarters · filed 2026-09-02 | $1.19M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $338.00K 10-Q · filed 2026-04-27 | $685.00K derived: sum of 2 quarters · filed 2026-09-02 | $985.00K derived: sum of 3 quarters · filed 2026-09-02 | $1.28M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $347.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $647.00K derived: sum of 2 quarters · filed 2026-09-02 | $947.00K derived: sum of 3 quarters · filed 2026-09-02 | $1.39M S-4 · filed 2026-09-02 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-10-29 | $600.00K derived: sum of 2 quarters · filed 2026-09-02 | $1.04M 10-Q · filed 2025-10-29 | $1.32M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $300.00K S-4 · filed 2026-09-02 | $697.00K S-4 · filed 2026-09-02 | $1.02M derived: sum of 3 quarters · filed 2026-09-02 | $1.42M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $353.00K 10-Q · filed 2026-04-27 | $722.00K derived: sum of 2 quarters · filed 2026-09-02 | $1.12M derived: sum of 3 quarters · filed 2026-09-02 | $1.52M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $369.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $769.00K derived: sum of 2 quarters · filed 2026-09-02 | $1.17M derived: sum of 3 quarters · filed 2026-09-02 | $1.59M S-4 · filed 2026-09-02 |
| 2024-09-30 | $400.00K 10-Q · filed 2025-10-29 | $800.00K derived: sum of 2 quarters · filed 2025-10-29 | $1.22M 10-Q · filed 2025-10-29 | $1.79M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $400.00K 10-Q · filed 2025-07-29 | $855.00K 10-Q · filed 2025-07-29 | $1.39M derived: sum of 3 quarters · filed 2025-07-29 | $1.89M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $479.00K 10-Q · filed 2025-05-01 | $987.00K derived: sum of 2 quarters · filed 2025-05-01 | $1.49M derived: sum of 3 quarters · filed 2025-05-01 | $2.09M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $508.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.01M derived: sum of 2 quarters · filed 2025-02-25 | $1.61M derived: sum of 3 quarters · filed 2025-02-25 | $2.17M 10-K · filed 2025-02-25 |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-13 | $1.10M derived: sum of 2 quarters · filed 2024-11-13 | $1.66M 10-Q · filed 2024-11-13 | $2.26M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $600.00K 10-Q · filed 2024-07-31 | $1.13M 10-Q · filed 2024-07-31 | $1.76M derived: sum of 3 quarters · filed 2024-07-31 | $2.36M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $566.00K 10-Q · filed 2024-05-13 | $1.16M derived: sum of 2 quarters · filed 2024-05-13 | $1.76M derived: sum of 3 quarters · filed 2024-05-13 | $2.46M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.19M derived: sum of 2 quarters · filed 2024-02-27 | $1.89M derived: sum of 3 quarters · filed 2024-02-27 | $2.41M 10-K · filed 2024-02-27 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-07 | $1.30M derived: sum of 2 quarters · filed 2023-11-07 | $1.82M 10-Q · filed 2023-11-07 | $2.46M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $700.00K 10-Q · filed 2023-08-03 | $1.21M 10-Q · filed 2023-08-03 | $1.86M derived: sum of 3 quarters · filed 2023-08-03 | $2.46M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $536.00K 10-Q · filed 2023-05-15 | $1.16M derived: sum of 2 quarters · filed 2023-06-26 | $1.76M derived: sum of 3 quarters · filed 2023-06-26 | $2.46M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $621.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $1.22M derived: sum of 2 quarters · filed 2023-06-26 | $1.92M derived: sum of 3 quarters · filed 2023-06-26 | $2.52M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $600.00K 10-Q · filed 2022-11-08 | $1.30M derived: sum of 2 quarters · filed 2022-11-08 | $1.89M 10-Q · filed 2022-11-08 | $2.64M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $700.00K 10-Q · filed 2022-08-11 | $1.27M 10-Q · filed 2022-08-11 | $2.04M derived: sum of 3 quarters · filed 2023-06-26 | $2.54M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $603.00K 10-Q · filed 2022-05-09 | $1.34M derived: sum of 2 quarters · filed 2023-06-26 | $1.84M derived: sum of 3 quarters · filed 2023-06-26 | $2.44M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $733.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $1.23M derived: sum of 2 quarters · filed 2023-06-26 | $1.83M derived: sum of 3 quarters · filed 2023-06-26 | $2.38M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-04 | $1.10M derived: sum of 2 quarters · filed 2021-11-04 | $1.65M 10-Q · filed 2021-11-04 | $2.16M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-10 | $1.09M 10-Q · filed 2021-08-10 | $1.66M derived: sum of 3 quarters · filed 2023-06-23 | $2.16M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | $539.00K 10-Q · filed 2021-05-06 | $1.06M derived: sum of 2 quarters · filed 2023-06-23 | $1.56M derived: sum of 3 quarters · filed 2023-06-23 | $2.06M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | $519.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $1.02M derived: sum of 2 quarters · filed 2023-06-23 | $1.52M derived: sum of 3 quarters · filed 2023-06-23 | $2.05M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $500.00K 10-Q · filed 2020-11-10 | $1.00M derived: sum of 2 quarters · filed 2020-11-10 | $1.53M 10-Q · filed 2020-11-10 | $2.01M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-11 | $1.02M 10-Q · filed 2020-08-11 | $1.51M derived: sum of 3 quarters · filed 2020-08-11 | $1.91M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $504.00K 10-Q · filed 2020-05-13 | $1.01M derived: sum of 2 quarters · filed 2020-05-13 | $1.41M derived: sum of 3 quarters · filed 2020-05-13 | $1.61M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $909.00K derived: sum of 2 quarters · filed 2020-03-05 | $1.11M derived: sum of 3 quarters · filed 2020-03-05 | $1.34M 10-K · filed 2020-03-05 |
| 2018-09-30 | $400.00K 10-Q · filed 2019-11-14 | $600.00K derived: sum of 2 quarters · filed 2019-11-14 | $836.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $200.00K 10-Q · filed 2019-08-26 | $377.00K 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |